A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical is set to release its quarterly earnings on October 29, 2024, with analysts expecting an EPS of $0.52. The company's past performance shows significant stock price movements following earnings announcements. Analysts rate Biomarin as 'Outperform' with a price target suggesting a 44.63% upside. Biomarin's financial metrics, such as revenue growth and net margin, are strong compared to peers, although its market capitalization is below industry benchmarks.
October 28, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomarin Pharmaceutical is expected to announce its quarterly earnings with an EPS of $0.52. The stock has shown significant price movements post-earnings in the past. Analysts rate it 'Outperform' with a potential 44.63% upside, indicating positive sentiment.
Biomarin's upcoming earnings release is highly anticipated, with analysts expecting a positive EPS. The stock has historically reacted strongly to earnings announcements, and the current 'Outperform' rating with a significant upside suggests positive market sentiment. This could lead to a short-term increase in stock price if earnings meet or exceed expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100